Drug Profile
CKD 712
Alternative Names: CKD-712Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Alkaloids; Isoquinolines
- Mechanism of Action I-kappa B kinase inhibitors; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Sepsis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Sepsis in South Korea (IV)
- 13 May 2010 Phase I development is ongoing in South Korea
- 03 May 2010 CKD 712 is available for licensing worldwide (http://210.92.140.4/research.htm)